StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Investment analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Thursday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE BTX opened at $6.72 on Thursday. The company has a market cap of $395.31 million, a PE ratio of -2.96 and a beta of 4.61. The stock’s 50 day simple moving average is $2.01 and its 200-day simple moving average is $1.35. Brooklyn ImmunoTherapeutics has a 1-year low of $6.57 and a 1-year high of $8.31.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.